References
- Davies SJ, Westin AA, Castberg I, Lewis G, Lennard MS, Taylor S, et al. Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand 2010;122:444–53.
- Aguirre C, Haramburu F. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux]. Therapie 1995;50:563–9.
- Hood S, Orr K, Bennett L, Davies S. Severe laryngeal dystonia in a patient receiving zuclopenthixol “Acuphase” and fluoxetine. Australas Psychiatry 2010;18:174–6.
- Jeong S, Woo MM, Flockhart DA, Desta Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol 2009;64: 867–75.